Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Visit

COMy 2023 | Insights into the biology of high-risk myeloma and advances being made in this space

Gareth Morgan • 12 May 2023

COMy 2023

Multiple Myeloma Antibodies

Gareth Morgan, MD, PhD, FRCP, FRCPath, NYU Langone Health, New York City, NY, shares some insights into the biology of high-risk multiple myeloma, highlighting the role of TP53 mutation and various translocations in high-risk disease. Prof. Morgan also explains that there are major advances being made in our understanding of high-risk myeloma and several ongoing clinical trials addressing the outcomes of these patients. This interview took place at the 9th World Congress on Controversies in Multiple Myeloma (COMy) 2023, held in Paris, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

How cutting-edge research is changing outcomes in myeloma and the need for novel endpoints in trials

Gareth Morgan • 10 Dec 2023

Investigating the non-coding myeloma genome

Gareth Morgan • 10 Dec 2023

Structural variation is a key driver of relapse and aggressive clinical behavior in multiple myeloma

Gareth Morgan • 10 Dec 2023

Personalizing treatment in multiple myeloma: approaching patients with t(4;14) and t(11;14)

Gareth Morgan • 29 Sep 2023

Related Videos

Looking forward to COMy 2024: celebrating 10 years

Mohamad Mohty • 17 Apr 2024

Overcoming barriers to treating older patients with myeloma

Sergio Giralt • 16 Apr 2024

The potentially curative role of CAR-T therapy in myeloma

Sergio Giralt • 16 Apr 2024

Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines

Monika Engelhardt • 16 Apr 2024